HC Wainwright Reiterates Buy Rating for BioLineRx (NASDAQ:BLRX)

HC Wainwright reissued their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $21.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.10) EPS.

Separately, StockNews.com began coverage on shares of BioLineRx in a research report on Thursday, October 31st. They issued a “hold” rating for the company.

BioLineRx Trading Down 1.5 %

NASDAQ BLRX opened at $0.44 on Wednesday. BioLineRx has a one year low of $0.39 and a one year high of $1.93. The company’s 50 day moving average price is $0.53 and its 200 day moving average price is $0.63. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The firm has a market capitalization of $35.54 million, a price-to-earnings ratio of -0.99 and a beta of 1.48.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. On average, sell-side analysts predict that BioLineRx will post -0.25 EPS for the current year.

Institutional Trading of BioLineRx

Hedge funds have recently made changes to their positions in the stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx during the second quarter worth approximately $70,000. CVI Holdings LLC acquired a new stake in shares of BioLineRx during the second quarter worth approximately $462,000. Finally, Atria Investments Inc grew its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares in the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.